XBiotech Inc. (XBIT), a biopharmaceutical company, on Monday reported authorization of patient enrollment for the Phase 2 V-SPINE trial for Vilamakitug in treating active axial spondyloarthritis.
Vilamakitug (XP2001 or Natrunix) is an IgG4 monoclonal antibody neutralizing interleukin 1-alpha, a pro-inflammatory cytokine that promotes synovial and entetheseal inflammation, osteoclast-mediated bone resorption, cartilage degradation, and inflammatory joint pain in spondyloarthritis. By targeting the cytokine, vilamakitug shows potential to reduce structural damage and disease activity. The Phase 2 V-SPINE (PT064) is a planned randomized, double-blind, placebo-controlled trial, that expects to enrol 150 patients of active axial spondyloarthritis (axSpA). Patients will be administered a weekly subcutaneous injection of vilamakitug, followed by a 12-week open-label extension. The primary endpoint will be measured using the ASAS40 response at week 16.
The company submitted an investigational new drug (IND) application for vilamakitug, and successfully completed the 30-day review period without a clinical hold. The FDA granted clearance for the trial, thus enabling patient enrolment.
XBIT closed Monday at $2.35, up 0.43%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.